Bloemendal, Martine
van Willigen, Wouter W.
Bol, Kalijn F.
Boers-Sonderen, Marye J.
Bonenkamp, Johannes J.
Werner, J. E. M.
Aarntzen, Erik H. J. G.
Koornstra, Rutger H. T.
de Groot, Jan Willem B.
de Vries, I. Jolanda M.
van der Hoeven, Jacobus J. M.
Gerritsen, Winald R.
de Wilt, Johannes H. W.
Funding for this research was provided by:
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (837004014, Vici grant 91814655)
Article History
Received: 19 December 2018
First Online: 4 March 2019
Compliance with Ethical Standards
:
: WR.G. received speaker fees from Astellas, Bayer, Merck Sharp & Dohme (MSD), and the European Society for Medical Oncology, participated in advisory boards of Amgen, Bayer, Bristol-Myers Squibb, Curevac, Dendreon, IQVIA, Janssen-Cilag, Merck (MSD), Morphosys, and Sanofi, and received research grants from Astellas, Amgen, Bayer, Janssen-Cilaq, and Sanofi. R. H. T. K. has received speaker fees from BMS, MSD, and Roche. He has advisory relationships with BMS, MSD, Novartis, and Roche. He received research grants from BMS and Roche. For the remaining authors, no conflicts of interest are declared.